Regulus Therapeutics Inc. (NASDAQ:RGLS) shares traded down 2.7% during trading on Tuesday . The company traded as low as $3.49 and last traded at $3.54, with a volume of 248,763 shares trading hands. The stock had previously closed at $3.64.

A number of research analysts recently commented on the stock. BMO Capital Markets lowered shares of Regulus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $16.00 to $4.00 in a research note on Tuesday, June 28th. Wells Fargo & Co. assumed coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 3rd. They set a “buy” rating on the stock. Needham & Company LLC reiterated a “buy” rating on shares of Regulus Therapeutics in a research note on Tuesday, May 3rd. Cowen and Company reiterated a “buy” rating on shares of Regulus Therapeutics in a research note on Monday, May 2nd. Finally, FBR & Co reiterated an “outperform” rating and set a $9.00 price objective (down previously from $30.00) on shares of Regulus Therapeutics in a research note on Tuesday, June 28th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.17.

The company has a 50-day moving average price of $3.50 and a 200-day moving average price of $5.61. The stock’s market capitalization is $182.76 million.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.02. On average, equities research analysts forecast that Regulus Therapeutics Inc. will post ($1.59) earnings per share for the current fiscal year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.